Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients with...

One step forward

Religiosity and telomere length: One step forward, one step back.

a Harvard T.H. Chan School of Public Health, Department of Epidemiology, Program on Integrative Knowledge and Human Flourishing, Harvard University, National Consortium on Psychosocial Stress, Spirituality, and Health, United States b Harvard Medical School, Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities, National Consortium on Psychosocial Stress, Spirituality, ...

Assessing the MGMT status in glioblastoma: one step forward, two steps back?

O 6-methylguanin-DNA-methyltransferase (MGMT) would undoubtedly be the molecule of the decade in the field of glioblastoma. More than 15 years ago, the first reports indicated that high activity of this protein in glioma tissue was associated with limited benefit from alkylating-agent chemotherapy, at that time largely nitrosoureas 1. In 2000, methylation of the promoter region of the MGMT gene...

One step forward and two steps back.